managing innovation evista case morgane … maël bourguignon jonathan calvet axel caborderie
TRANSCRIPT
Managing Innovation Evista Case
Morgane …Maël BourguignonJonathan CalvetAxel Caborderie
SummaryI. INTRODUCTION
– Background
II. MARKET CONSTRAINTS AND PROBLEMATIC
– Threats : Generics / « Me too »
– Environmental constraints : Formularies / Laws
– Problematic
III. DEVELOPMENT PROCESS AND ORGANIZATION
– Development process / Time to Market
– « Heavyweight » management approach
IV. CONCLUSION :
– To go Further
1876. Creation of ELI LILLY and Company by Colonel Eli Lilly, pharmaceutical chemist and Civil war veteran.
Background
1930-80. ELI LILLY continued to develop insulin product family and treatment of endocrine diseases.
Background
1920. First Blockbuster for treatment of diabetes: Insulin
Background
1950s. Development of Ceclor : top-selling antibiotic of the world.
Background
1980. Introduction of Humilin using recombinant DNA technology : improve diabetes treatment.
Background
1986. Commercialisation of Prozac : drug for central nervous system.
Background
1996. Zyprexa : Anti-psychotic for treatment of schizophrenia.
Background
1990-97. Restructuring and focus on fighting cancer and cardiovascular diseases : Launch of ReoPro, anti-platelet agent and Gemzar, oncology product.
Background
2005. Eli Lilly registered 14,6 billion $ of global revenues
Background
The problematic
Considering the increasing threats within the pharmaceutical industry, How can Eli Lilly remain competitive?
Conclusion
• Time to market : a better approach taking into account the market constraints.
• « Heavyweight » approach: give the priority to the future potential blockbuster.
Conclusion
• To go further :– Should we apply this approach to
the commercialization of new drugs ?
– On which criterions ?– For which costs ?– Should we have to delay or stop
other projects ?